The U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced yesterday that it launched a phase 1 clinical study evaluating an investigational messenger RNA (mRNA) vaccine to prevent infection with the Nipah virus.
The mRNA-1215 vaccine candidate is manufactured by Moderna, Inc. and was developed in collaboration with NIAID’s Vaccine Research Center.
mRNA-1215 will be tested in a dose-escalation clinical trial to evaluate its safety, tolerability, and ability to generate an immune response in 40 healthy adults in Maryland.
Read More
